dismiss

Pre-Bid now on over 2,500 items! We go LIVE on June 6th, 10AM EDT!

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Cardiology Homepage

Siemens and HeartIT ink deal for cardiovascular MR software Six of the 15 largest cardiac MR centers in the U.S. already use Precession

Continuity of care is more important than speed in the case of chronic heart failure New research shows improved outcomes for patients returned to same hospital

The latest news in defibrillators, patient monitoring and biomedical testing equipment Devices that underscore the importance of patient safety

IBM and Sutter Health partner to predict heart failure risk using EHR data Using AI to stop cardiovascular events before they happen

Boston Scientific's S-ICD system found to have low complication rate Promising study outcome for leadless cardiac implant

Study reveals low adherence to nuclear cardiology dose reduction guidelines Most sites implemented less than half of metrics

One in five AEDs in four regions failed at least one phase of testing Five percent wouldn't even turn on at all

GE and Lantheus extend flurpiridaz F 18 agreement to 2020 Companies committed to coronary PET agent development and commercialization

U.S. and Chinese researchers work to standardize MR stroke protocols with 3-D model Better understanding ICAD with the aid of high-res imaging

Siemens partners with Ebit for Suitestensa cardio IT system Agreement initially in Germany, but with plans to expand to other countries

Transcatheter aortic valve replacement
Photo courtesy of Mayo Clinic

Edwards Lifesciences’ CENTERA valve demonstrates excellent clinical outcomes in new study

by Lauren Dubinsky , Senior Reporter
Treating transcatheter aortic valve replacement patients with Edwards Lifesciences’ CENTERA valve yields excellent clinical outcomes, according to a study presented today at EuroPCR 2017 in Paris.

The company announced that it was developing this repositionable, self-expanding valve in its December 2016 Investor Fact Sheet. It can be delivered through a low-profile 14-French delivery system that’s equipped with a motorized handle for stable valve deployment.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



"The Edwards CENTERA valve demonstrates extremely favorable early clinical safety and performance outcomes in the high surgical risk TAVR population," Dr. Didier Tchétché, of Clinique Pasteur in Toulouse, France, who presented the data, said in a statement.

"In addition to excellent patient outcomes, the valve also offers several unique features and an innovative tissue design, all of which simplify the procedure for clinicians,” he adds.

The 203 patients evaluated for the study had severe, symptomatic aortic stenosis and were too high-risk for open-heart surgery. A study published in Lancet found that more than one in eight people aged 75 and older have moderate or severe aortic stenosis (AS).

All of the patients were treated with the CENTERA valve via the transfemoral route, and 174 were under conscious sedation. After 30 days, 99 percent of the patients survived and 2.5 percent suffered a disabling stroke, which is considered a low rate.

Only 4.9 percent of the patients required a permanent pacemaker, which is the lowest rate ever reported in a multicenter trial for a self-expanding valve. In addition, there was a low .6 percent rate of moderate paravalvular leaks and no severe paravalvular leaks.

The patients were enrolled from 23 centers located in Europe, Australia and New Zealand. For the next five years, they will be monitored for additional research.

The CENTERA valve is still an investigational device, so it isn’t commercially available in any country to date. Edwards predicts that it will receive CE mark during the fourth quarter of this year.

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED